-
Article
Open AccessDevelopment of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma
Antibody engineering can tailor the design and activities of therapeutic antibodies for better efficiency or other advantageous clinical properties. Here we report the development of ISB 1442, a fully human bi...
-
Chapter and Conference Paper
PHSD—A Microscopic Transport Approach for Strongly Interacting Systems
We present the basic ideas of the Parton–Hadron–String Dynamics (PHSD) transport approach which is a microscopic covariant dynamical model for strongly interacting systems formulated on the basis of Kadanoff–B...
-
Article
Friction Correction of Austenite Flow Stress Curves Determined under Axisymmetric Compression Conditions
The experimental flow stress curves of structural steels obtained from axisymmetric compression tests conducted under hot-working conditions very often include the frictional effects present at the tool/specim...
-
Chapter
Total Marrow Irradiation in Multiple Myeloma: The French Myeloma Group Experience
Despite advances in drug treatments, multiple myeloma almost always remains a fatal disease. Technical advances in radiotherapy enable total marrow irradiation (TMI) by intensity-modulated radiation therapy (I...
-
Article
Open AccessHeavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients
Novel anti-myeloma agents have improved patient response rates, which are historically based on reductions of the M-protein. These methods can be inaccurate for quantifying M-proteins at low concentrations. We...
-
Article
Open AccessDiagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel
Solitary plasmacytoma is an infrequent form of plasma cell dyscrasia that presents as a single mass of monoclonal plasma cells, located either extramedullary or intraosseous. In some patients, a bone marrow as...
-
Article
Open AccessPrevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network
During the last few years, several new drugs have been introduced for treatment of patients with multiple myeloma, which have significantly improved treatment outcome. All of these novel substances differ at l...
-
Article
Open AccessEfficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes
Autologous stem cell transplantation (ASCT) is a standard treatment for eligible multiple myeloma (MM) patients, but many patients will relapse after ASCT and require subsequent therapy. The proteasome inhibit...
-
Article
Open AccessExpressed fusion gene landscape and its impact in multiple myeloma
Multiple myeloma is a plasma cell malignancy characterized by recurrent IgH translocations and well described genomic heterogeneity. Although transcriptome profiles in multiple myeloma has been described, landsca...
-
Article
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study
Introduction of new myeloma therapies offers new options for patients refractory to immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs). In this multicenter study, patients with relapsed multiple my...
-
Article
New drugs in myeloma: beware of phase I trial results, beware of cost and demand for new trials
-
Article
Second-degree relative donors for T-replete haploidentical allogeneic stem cell transplantation with high-dose post-transplant cyclophosphamide: toward crossing the major HLA barrier
-
Article
Lymphocyte expansion after unrelated cord blood allogeneic stem cell transplantation in adults
Limited information is available regarding the incidence and features of lymphocyte expansions after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Large granular lymphocytes (LGL) expansions ...
-
Article
Carboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC+/−R) is an effective treatment with low toxicity in Hodgkin’s and non-Hodgkin’s lymphomas
The DHAP regimen (high-dose cytarabine in combination with dexamethasone and cisplatin) with or without rituximab (DHAP+/−R) is one of the most common regimens in daily practice. It is considered the standard ...
-
Article
Open AccessCarfilzomib–dexamethasone vs bortezomib–dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR
The randomized phase 3 study ENDEAVOR demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for carfilzomib and dexamethasone (Kd) vs bortezomib and ...
-
Article
Monoclonal antibody therapy in multiple myeloma
The therapeutic landscape of multiple myeloma (MM) has evolved spectacularly over the past decade with the discovery and validation of proteasome inhibitors and immunomodulatory agents as highly active agents,...
-
Article
Open AccessCarfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment
Carfilzomib, a proteasome inhibitor, is approved as monotherapy and in combination with dexamethasone or lenalidomide–dexamethasone (Rd) for relapsed or refractory multiple myeloma. The approval of carfilzomib...
-
Article
Open AccessImpact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study
The randomized phase 3 ENDEAVOR study (N=929) compared carfilzomib and dexamethasone (Kd) with bortezomib and dexamethasone (Vd) in relapsed multiple myeloma (RMM). We performed a subgroup analysis from ENDEAVOR ...
-
Article
Observables and open problems for NICA
The restoration of chiral symmetry in hot dense nuclear systems in competition with a transition to deconfined matter in central nucleus-nucleus collisions at NICA energies is a central problem of nuclear phys...
-
Article
Rituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naive rituximab follicular lymphoma patients: a single institution experience
We retrospectively evaluated the role of rituximab (R) in maintenance treatment after autologous stem cell transplantation performed in patients with relapsed follicular lymphoma. We compared the outcome of 67...
